Bayer said it will voluntarily withdraw its follicular lymphoma drug Aliqopa from the US after a confirmatory trial disappointment, marking the third PI3K inhibitor to be pulled in recent years.
A Bayer spokesperson told Endpoints News in an email that the Phase III CHRONOS-4 trial of…
Click here to view original post
